PrintThe Burrill Report
Steve Burrill offers a view of the state of the industry in his opening remarks at this year's annual Burrill Personalized Medicine Meeting in San Francisco.
October 25, 2010
December 31, 2010
http://www.burrillreport.com/article-a_view_of_the_state_of_the_industry.html
INSIGHT
A View of the State of the Industry
Insight with Steve Burrill: October 25, 2010[Please login to post comments]
- The Curtain Rises on 2011
Podcast: January 10, 2011 Read More - Life Sciences Venture Capital Flows in 2010
Regional breakdown shows most money goes to San Francisco Bay Area, but Boston area sees greatest gains. Read More - Xoma Lands Deep-Pocketed French Partner
Servier to pay up to $505 million for experimental antibody to treat diabetes and other conditions. Read More - When NICE News Isn’t So Nice for Roche
UK advisory body will consider whether to allow the use of Avastin to treat wet age-related macular degeneration. Read More - Policy Victories of 2010 and the Battles Ahead in the New Year
Podcast: January 3, 2011 Read More - Life Sciences Companies Raise Record Amounts of Capital
Venture financings more than double while public companies go for debt. Read More - A Conversation with Eli Lilly's John Lechleiter
InSight with Steve Burrill: November 5, 2010 Read More - A Conversation About the Future of Molecular Diagnostics
InSight with Steve Burrill: December 7, 2010 Read More - Stem Cell Research Under Attack
InSight with Steve Burrill: August 30, 2010 Read More - Two Wrongs
Critics of the nation’s move toward government-run healthcare are misreading the FDA’s Avastin decision. Read More
.gif)
.gif)
- Health Care Law Ruled Unconstitutional
The New york Times - Bayer to Spend $4.1 Billion on Research in 2011 as Xarelto Trials Near End
Bloomberg - Sanofi's chief gets U.S. lobby role as Kindler exits
Reuters - Pfizer’s Chairman and Chief Retires Unexpectedly
The New York Times - Arsenic-eating bacteria point to new life forms
The Scientist - Merck to buy SmartCells to gain diabetes product
Reuters - Overweight People, Not Just Obese, More Likely to Die Sooner, Study Says
Bloomberg - Orexigen Options Suggest Contrave Diet Pill May Avoid Arena, Vivus Delays
Bloomberg - Biosimilars will be challenging for FDA, speakers say
The Hill - EU guidelines clear way for biosimilar antibodies
Reuters